Reciprocal blocking studies performed with 10 αIIb/β3–specific mAbs
| . | Blocking (unlabeled) monoclonal . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 10E5 . | 290.5 . | 184.2 . | 312.8 . | 312.2 . | 312.6 . | 7E3 . | AP2 . | AP3 . | 330.1 . | |
| 10E5 | 100.0 | 99.6 | 24.8 | 37.2 | 10.9 | 4.5 | 3.7 | 23.9 | 5.7 | 8.6 |
| 290.5 | 99.6 | 100.0 | 12.5 | 14.1 | 5.3 | 0.5 | 8.6 | 25.7 | 4.0 | 15.4 |
| 184.2 | 29.7 | 24.9 | 100.0 | 99.0 | 23.4 | 14.6 | 28.9 | 36.8 | 5.2 | 33.4 |
| 312.8 | 43.4 | 37.1 | 99.7 | 100.0 | 16.4 | 15.6 | 17.9 | 52.2 | 21.7 | 0.0 |
| 312.2 | 60.7 | 74.2 | 40.7 | 20.8 | 100.0 | 100.0 | 43.2 | 3.1 | 41.6 | 18.4 |
| 312.6 | 40.5 | 43.0 | 12.4 | 5.3 | 100.0 | 100.0 | 7.0 | 20.3 | 20.8 | 3.7 |
| 7E3 | 40.6 | 42.7 | 14.3 | 16.3 | 13.6 | 18.6 | 100.0 | 99.4 | 22.1 | 8.2 |
| AP2 | 18.1 | 34.8 | 29.4 | 62.8 | 16.8 | 7.7 | 98.2 | 100.0 | 7.7 | 0.0 |
| AP3 | 10.1 | 19.2 | 25.1 | 43.7 | 14.5 | 26.1 | 34.6 | 12.4 | 100.0 | 100.0 |
| 330.1 | 6.9 | 4.5 | 7.8 | 24.0 | 10.0 | 14.1 | 25.1 | 10.3 | 99.6 | 100.0 |
| . | Blocking (unlabeled) monoclonal . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 10E5 . | 290.5 . | 184.2 . | 312.8 . | 312.2 . | 312.6 . | 7E3 . | AP2 . | AP3 . | 330.1 . | |
| 10E5 | 100.0 | 99.6 | 24.8 | 37.2 | 10.9 | 4.5 | 3.7 | 23.9 | 5.7 | 8.6 |
| 290.5 | 99.6 | 100.0 | 12.5 | 14.1 | 5.3 | 0.5 | 8.6 | 25.7 | 4.0 | 15.4 |
| 184.2 | 29.7 | 24.9 | 100.0 | 99.0 | 23.4 | 14.6 | 28.9 | 36.8 | 5.2 | 33.4 |
| 312.8 | 43.4 | 37.1 | 99.7 | 100.0 | 16.4 | 15.6 | 17.9 | 52.2 | 21.7 | 0.0 |
| 312.2 | 60.7 | 74.2 | 40.7 | 20.8 | 100.0 | 100.0 | 43.2 | 3.1 | 41.6 | 18.4 |
| 312.6 | 40.5 | 43.0 | 12.4 | 5.3 | 100.0 | 100.0 | 7.0 | 20.3 | 20.8 | 3.7 |
| 7E3 | 40.6 | 42.7 | 14.3 | 16.3 | 13.6 | 18.6 | 100.0 | 99.4 | 22.1 | 8.2 |
| AP2 | 18.1 | 34.8 | 29.4 | 62.8 | 16.8 | 7.7 | 98.2 | 100.0 | 7.7 | 0.0 |
| AP3 | 10.1 | 19.2 | 25.1 | 43.7 | 14.5 | 26.1 | 34.6 | 12.4 | 100.0 | 100.0 |
| 330.1 | 6.9 | 4.5 | 7.8 | 24.0 | 10.0 | 14.1 | 25.1 | 10.3 | 99.6 | 100.0 |
Platelets were incubated with saturating quantities of the unlabeled (blocking) mAbs listed in the first horizontal row or with buffer alone. After a single wash with buffer solution, biotinylated mAbs listed in the first column were added and bound Ab was detected with PE-labeled streptavidin using flow cytometry. Values shown (average of triplicate determinations) indicate the extent to which “blocking” mAbs reduced the signal obtained with unblocked platelets (expressed as percentage of inhibition).
Bold indicates reactions inhibited by 90% or more; and underlined values, reactions inhibited by 45% or more.